Regeneron Pharmaceuticals' GAAP net income for 9 months of 2023 was $2.794 billion, down 11% from $3.141 billion in the prior year. Revenue increased 10.5% to $9.683 billion from $8.759 billion a year earlier.

Regeneron Pharmaceuticals' GAAP net income for 6 months of 2023 was $1.786 billion, down 2.2% from $1.826 billion in the prior year. Revenue increased 8.6% to $6.32 billion from $5.822 billion a year earlier.

Regeneron Pharmaceuticals' GAAP net income for 3 months of 2023 was $817.8 million, down 16% from $973.5 million in the previous year. Revenue increased 6.6% to $3.162 billion from $2.965 billion a year earlier.

Regeneron Pharmaceuticals' GAAP net income for 2022 was $4.338 billion, down twofold from $8.075 billion in the previous year. Revenue fell 24.3% to $12.173 billion from $16.072 billion a year earlier.